Get the latest news, insights, and market updates on HRTX (Heron Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Heron Therapeutics Q4 Earnings Call Highlights
Heron Therapeutics (NASDAQ:HRTX) reported fourth-quarter and full-year 2025 results while outlining plans to increase commercial investment in 2026 to build on what management described as an inflection in acute care demand that emerged earlier than expected. 2025 financial results and profitabilit Feb 26, 2026 - $HRTX
Heron Therapeutics: Q4 Earnings Snapshot
On a per-share basis, the Cary, North Carolina-based company said it had a loss of 2 cents. The pharmaceutical company posted revenue of $40.6 million in the period. For the year, the company reported a loss of $20.2 million, or 12 cents per share. Feb 26, 2026 - $HRTX
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Feb 26, 2026 - $HRTX
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
– ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and h Feb 26, 2026 - $HRTX
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide partici Feb 17, 2026 - $HRTX
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M
“We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year.” Preliminary Q4 and FY25 Updates: Net revenue of approximately $40.5M for the three months ended December 31. ZYNRELEF net revenue of approximately $12.5M for the three months ended Jan 10, 2026 - $HRTX
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®,” said Craig Collard, Chief Executive Officer of Heron. “In addition to our revenue growth, we are extremely pleased wit Jan 9, 2026 - $HRTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple